Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bexxar tositumomab iodine-131 labeled anti-CD20 monoclonal antibody regulatory update

The FDA extended by up to three months its review of Corixa's Bexxar radioimmunotherapy for non-Hodgkin's

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE